- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- Study: Daily aspirin use may reduce risk of ovarian cancer by 20%
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Harvard Heart Letter: Many consumers who supplement with aspirin don't need to
NEW YORK — Eye care company Alcon has launched a treatment for pain and inflammation resulting from cataract surgery, the company said Monday.
The company said Ilevro (nepafenac) ophthalmic suspension was a nonsteroidal anti-inflammatory drug and once-daily treatment for cataract surgery patients.
"We are committed to developing products that continue to improve patient care," Alcon VP and general manager for U.S. pharmaceuticals Gary Menichini said. "This launch represents the dedication of the [research and development] team to engineer and efficacious, innovative formulation with a reduced dosing regimen."